NCT00888576已完成不适用
A Registry Study to Describe the Implications of Therapeutic Management of Etanercept in Patients With Rheumatoid Arthritis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 441
- 试验地点
- 1
- 主要终点
- Safety: Proportion of patients discontinued from etanercept as a result of an adverse event by Week 24, laboratory exam findings, incidence of adverse events, and vital signs and physical exam findings. Efficacy: Disease Activity Score 28 at week 20.
研究概览
简要总结
The purpose of this study is to develop a registry with safety and efficacy data on the use of etanercept in clinical practice in Taiwan.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Main Inclusion Criteria: 1) Male or female patients aged > 20 years; 2) Patients who have already been selected and approved under the Taiwan National Health Insurance Program to receive 24 weeks of etanercept for rheumatoid arthritis. Main
排除标准
- •Exclusion Criteria: None
结局指标
主要结局
Safety: Proportion of patients discontinued from etanercept as a result of an adverse event by Week 24, laboratory exam findings, incidence of adverse events, and vital signs and physical exam findings. Efficacy: Disease Activity Score 28 at week 20.
时间窗: 24 weeks
次要结局
- Global health assessment; Erythrocyte sedimentation rate; Number of swollen or tender joints; C-reactive protein; Proportion of patients having worsened DAS 28 and components of DAS 28,CRP than baseline; Etanercept approval-lag time.(24 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Registry On Efficacy and Safety Of Rosuvastatin, and Atorvastatin and Simvastatin In HypercholesterolaemiaHypercholesterolaemiaNCT01352897AstraZeneca800
Unknown
不适用
A Clinical Registry to Track the Real World Use of the Saber-C® Cervical Fusion DeviceCervical Disc DiseaseNCT06240221Research Source200
招募中
不适用
Database for the Assessment of Efficacy and Safety of BPH TreatmentLower Urinary Tract SymptomsBenign Prostatic HyperplasiaNCT03521648Dominik Abt500
已完成
3 期
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)Alzheimer's DiseaseNCT05463731Eli Lilly and Company1,667
招募中
不适用
A Study of Participants With β-Thalassemia Treated With Betibeglogene AutotemcelBeta-ThalassemiaNCT06271512bluebird bio150